The "RIG" portfolio aims for 50% income from defensive sectors and includes 83 stocks across 11+ sectors, focusing on ...

Wondering where to stay in Kodiak Island? I grew up here and will tell you about the best places on Kodiak Island, including the top hotels and the nearby attractions. For visitors, my top ...

Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients ("APIs") into Kodiak's proprietary biopolymer backbone to enable high drug-antibody ...

(Image Credits: Pixabay) Amid the growing burden of non-communicable diseases and ageing population, the pharmaceutical sector has thrived tremendously over the recent years. Industry leaders ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

“It seems like Mesoblast is finally getting there,” Wilkie said. Radiopharmaceuticals has emerged as one of hottest themes in the sector this year with Clarity Pharmaceuticals (ASX:CU6) a major ...

Kodiak Sciences is a biopharmaceutical company that develops ... proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)--$MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc ...

Kodiak Sciences is a biopharmaceutical company that develops ... proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

As you can see from the chart above the percentage of shares that are sold short for Tonix Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in ...

Kodiak Sciences is a biopharmaceutical company ... while pursuing a capital-efficient development approach. Agios Pharmaceuticals presented positive results from the Phase 3 ENERGIZE-T study ...